We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Studie COMMANDER-HF.
- Authors
Vítovec, Jiří
- Abstract
The COMMANDER-HF trial studied the effect of administering a low dose of rivaroxaban of 2.5 mg twice daily in patients with heart failure who had a sinus rhythm. The study showed that administration of rivaroxaban did not affect the primary composite endpoint (death from any cause, myocardial infarction, or stroke) compared to placebo. Additionally, no higher rate of major bleeding was observed. A post-hoc analysis showed a significantly lower incidence of ischaemic stroke with rivaroxaban.
- Publication
Intervencní a Akutní Kardiologie, 2019, Vol 18, Issue 3, p170
- ISSN
1213-807X
- Publication type
Article